STEVENSON, Md., Feb. 27, 2017 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Psychemedics Corporation (Nasdaq:PMD) (“Psychemedics” or the “Company”) common stock during the period between February 28, 2014 and January 31, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 3, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Psychemedics common stock during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Psychemedics’ Brazilian distributor, Psychemedics Brazil, was engaged in illegal anti-competitive practices and may be subject to further investigation by Brazil’s Administrative Council for Economic Defense as a result of the conduct.
According to the complaint, following a January 31, 2017 press release announcing that a Brazilian court had found Psychemedics Brazil in violation of anti-competition laws and liable for millions in losses, the value of Psychemedics shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Psychemedics common stock purchased on or after February 28, 2014 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 [email protected]


Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S.
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 



